Provectus Biopharmaceuticals Inc
provectusbio.comProvectus Biopharmaceuticals Inc (OTC: PVCT) is a clinical-stage biopharmaceutical company developing prescription drug candidates based on its proprietary rose bengal sodium (RBS) molecule. The company has no product revenues as of December 31, 2025, and funds operations through equity sales and financing arrangements. Its lead drug candidate, PV-10, is an intratumoral formulation of pharmaceutical-grade RBS that previously advanced through a multi-country, multi-center Phase 3 randomized controlled trial for locally advanced cutaneous melanoma (LACM), with Chemistry, Manufacturing and Control (CMC) data accepted by seven national drug regulatory agencies including the U.S. FDA, Germany's BfArM, Australia's TGA, France's ANSM, Italy's AIFA, Mexico's COFEPRIS, and Argentina's ANMAT. The company holds a proprietary, patented commercial-scale synthesis process for RBS as an active pharmaceutical ingredient (API). As of December 31, 2025, Provectus carried an accumulated deficit of $262,853,811 and its auditors have raised substantial doubt about its ability to continue as a going concern.
Products & Services
PV-10: an intratumoral drug candidate formulated from pharmaceutical-grade RBS (rose bengal sodium) API, previously studied in a Phase 3 trial for locally advanced cutaneous melanoma. Additional RBS formulations at various concentrations and routes of administration are in pre-clinical or early-stage development for other disease areas, with goals to file INDs or pursue co-development and out-licensing arrangements.
Revenue Model
Provectus generates no product revenue as of December 31, 2025. The company anticipates future revenues from product sales or out-licensing arrangements if drug candidates receive regulatory approval. Operations are funded through equity issuances and external financing. Unearned grant revenue appeared on prior balance sheets but showed a zero balance as of December 31, 2025.
Customers & Markets
No commercial customers as of December 31, 2025. Target end markets are oncology and other disease areas where RBS-based drug candidates may demonstrate clinical activity. Intended end users are patients and physicians in markets where regulatory approval may eventually be granted.
Geographic Exposure
Clinical development activities have spanned the United States, Germany, Australia, France, Italy, Mexico, and Argentina, based on the seven national regulatory agencies that reviewed CMC data for the prior Phase 3 trial. The company is incorporated in the United States.
Financial Snapshot
Loading...
